ANL 14.51 Increased By ▲ 0.13 (0.9%)
ASC 13.30 Increased By ▲ 0.10 (0.76%)
ASL 14.00 No Change ▼ 0.00 (0%)
BOP 8.37 Increased By ▲ 0.02 (0.24%)
BYCO 6.50 Increased By ▲ 0.05 (0.78%)
FCCL 17.80 Increased By ▲ 0.12 (0.68%)
FFBL 26.00 Decreased By ▼ -0.01 (-0.04%)
FFL 11.15 Decreased By ▼ -0.08 (-0.71%)
FNEL 10.72 Increased By ▲ 0.03 (0.28%)
GGGL 14.90 Decreased By ▼ -0.35 (-2.3%)
GGL 31.40 Increased By ▲ 0.55 (1.78%)
HUMNL 6.22 Decreased By ▼ -0.21 (-3.27%)
JSCL 17.00 Decreased By ▼ -0.10 (-0.58%)
KAPCO 31.48 Increased By ▲ 0.68 (2.21%)
KEL 3.20 Decreased By ▼ -0.03 (-0.93%)
MDTL 2.20 Decreased By ▼ -0.05 (-2.22%)
MLCF 33.80 Increased By ▲ 0.55 (1.65%)
NETSOL 97.25 Decreased By ▼ -1.15 (-1.17%)
PACE 4.22 Decreased By ▼ -0.10 (-2.31%)
PAEL 23.00 Decreased By ▼ -0.06 (-0.26%)
PIBTL 7.43 Decreased By ▼ -0.14 (-1.85%)
POWER 6.65 Increased By ▲ 0.10 (1.53%)
PRL 13.50 Decreased By ▼ -0.30 (-2.17%)
PTC 8.90 Increased By ▲ 0.03 (0.34%)
SILK 1.30 Decreased By ▼ -0.06 (-4.41%)
SNGP 39.66 Decreased By ▼ -0.14 (-0.35%)
TELE 16.40 Decreased By ▼ -0.45 (-2.67%)
TRG 87.40 Decreased By ▼ -1.50 (-1.69%)
UNITY 25.22 Decreased By ▼ -0.24 (-0.94%)
WTL 2.10 Decreased By ▼ -0.03 (-1.41%)
BR100 4,519 Increased By ▲ 21.96 (0.49%)
BR30 18,277 Decreased By ▼ -62.37 (-0.34%)
KSE100 44,114 Increased By ▲ 178.41 (0.41%)
KSE30 17,034 Increased By ▲ 94.74 (0.56%)

Coronavirus
LOW Source: covid.gov.pk
Pakistan Deaths
28,704
724hr
Pakistan Cases
1,283,886
41124hr
0.92% positivity
Sindh
475,097
Punjab
442,876
Balochistan
33,471
Islamabad
107,601
KPK
179,888
Business & Finance

Ferozsons pharma dismisses connection with unlicensed COVID-19 treatment

  • Ferozsons said that certain versions of this message also appear to link the name of Ferozsons Laboratories Limited with the launch.
06 Jun 2020

Pakistani pharmaceutical company, Ferozsons Laboratories has clarified that it is not associated with an unlicensed treatment for COVID-19, which is reportedly being imported from Bangladesh.

“A message is circulating on WhatsApp and social media, purportedly confirming the launch of an unlicensed treatment for COVID-19 imported from Bangladesh. The message quotes a price of Rs. 20,000 per injection, and promotes a 10-day COVID-19 treatment course at a package cost of Rs. 220,000,” Ferozsons said in a statement.

The company said that certain versions of this message also appear to link the name of Ferozsons Laboratories Limited with the launch. “We would like to clarify to the public at large that Ferozsons has no connection with the launch of the treatment being imported from Bangladesh and marketed in Pakistan.”

The pharma added that no product can be launched or promoted in Pakistan prior to regulatory approval from the Drug Regulatory Authority of Pakistan (DRAP).

Last month, Ferozsons Laboratories inked an agreement with Gilead Science Inc for the manufacture and sale of Remdesivir in the country. Remdesivir is a proprietary product of Gilead Sciences Inc., USA was granted Emergency Use Authorisation by the United States FDA on May 1, 2020.

“As a licensee of Gilead Sciences, Ferozsons, through its subsidiary BF Biosciences Limited, is committed to urgently making available a licensed product manufactured under a technology transfer of the Gilead manufacturing process for remdesivir, and to ethical communication at all times,” said the company.

We love hearing your feedback, please help us improve by answering these few survey questions

Comments

Comments are closed.